Reply to “Artificial intelligence’s potential in tailoring prescription of biological therapy for chronic rhinosinusitis”

We appreciate the letter to the editor by Minzoni et al,1Minzoni A. Gallo O. Artificial intelligence’s potential in tailoring prescription of biological therapy for chronic rhinosinusitis.J Allergy Clin Immunol Pract. 2023; 11: 3285-3286Abstract Full Text Full Text PDF Google Scholar in which they insightfully addressed our recent publication.2Goktas P. Karakaya G. Kalyoncu A.F. Damadoglu E. Artificial intelligence chatbots in allergy and immunology practice: where have we been and where are we going?.J Allergy Clin Immunol Pract. 2023; 11: 2697-2700Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar They explored the potential of artificial intelligence (AI) in customizing prescriptions of biologic drugs for chronic rhinosinusitis (CRS). We agree with their points and value their insightful contributions. Indeed, the application of AI in precision medicine presents an evolving and promising avenue. The authors provide an intriguing viewpoint on exploiting AI's abilities to address the complexities of CRS, aiming toward optimizing personalized treatments. We fully support the idea that AI's capacity to process substantial data and identify patterns can play an instrumental role in establishing personalized treatment strategies for complex conditions such as CRS. We agree that the utilization of AI to customize biologic therapy for CRS, based on individual patient characteristics, could enhance treatment efficacy, minimize side effects, and reduce costs. However, we wish to highlight the necessity for robust and high-quality datasets while developing such AI systems. Although AI is a powerful tool, its effectiveness is limited to the quality of data from which it learns. Moreover, incorporating AI-driven systems into clinical practice not only requires technical solutions but also demands careful attention to regulatory, ethical, and security concerns. Ensuring the privacy of patient data, fairness in predictions, and explicability of AI decisions are essential to maintain patient trust and safety. In conclusion, we join the authors in their enthusiasm regarding the great potential that AI offers in customizing the prescription of biologic drugs for CRS. This underlines the necessity for further research collaborations among clinicians, researchers, and data scientists. Such collaborative efforts can accelerate the integration of AI into clinical practice, leading to long-term benefits for patients suffering from CRS. Artificial intelligence’s potential in tailoring prescription of biologic therapy for chronic rhinosinusitisThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 10PreviewWe read with great interest the recent article by Goktas et al,1 suggesting a possible application of artificial intelligence (AI) in the field of Allergy and Immunology. We find that AI could also have an impactful use in the prescription of biological drugs in chronic rhinosinusitis (CRS). Full-Text PDF